中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 新药研究国家重点实验室
Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment

文献类型：期刊论文

作者Tang, Yisi1,2,3; Fan, Wufa4; Chen, Guihua1,2; Zhang, Meng2,5; Tang, Xueping1,2; Wang, Hairui2; Zhao, Pengfei2,6; Xu, Qin1; Wu, Zhibing1; Lin, Xiaoxi7
刊名NANO TODAY
出版日期2021-10-01
卷号40页码:14
关键词Cancer therapeutic vaccine Legumain Tumor-associated macrophage Trichosanthin Liposome Adjuvant
ISSN号1748-0132
DOI10.1016/j.nantod.2021.101244
通讯作者Wu, Zhibing(wuzhibing2021@126.com) ; Huang, Yongzhuo(yzhuang@simm.ac.cn)
英文摘要The efficient cancer vaccines require the codelivery of potent antigens and highly immunostimulatory adjuvants to the same antigen-presenting cells (APCs) to initiate a robust immune response. In this work, a clinically used trichosanthin served as an adjuvant to prepare a minimalist "all-in-one" vaccine that was a recombinant protein (termed rTL) of trichosanthin and an antigen legumain peptide. rTL was further incorporated into a nanovaccine delivery system (LrTL) using a liposome-encapsulated technology. LrTL can trigger a robust cytotoxic T lymphocytes (CTL) response by activation of APCs that enhance immunostimulatory cytokine secretion (e.g., TNF-alpha, IL-12, and IFN-gamma) and trigger T-cell immunity. By targeting tumor-associated macrophages (TAM), the nanovaccine carried out the anticancer immunity by eliminating TAM and thereby remodeling the tumor microenvironment. Subcutaneous immunization with the nano vaccine yielded a potent anti-tumor activity in several cancer models, including B16-F10, Lewis lung cancer (LLC), intracranial LLC xenograft, as well as CT-26 colon cancer. These findings demonstrate that the nanovaccine is a simple, safe, and robust strategy for cancer immunotherapy. The vaccination strategy offers a general applicability in various cancer types by targeting TAM and remodeling tumor microenvironment. (c) 2021 Elsevier Ltd. All rights reserved.
WOS关键词DENDRITIC CELLS ; PROGNOSTIC VALUE ; LEGUMAIN ; TRICHOSANTHIN ; DELIVERY ; IMMUNOTHERAPY ; ENHANCEMENT ; ADJUVANTS ; VACCINES ; IMMUNITY
WOS研究方向Chemistry ; Science & Technology - Other Topics ; Materials Science
语种英语
WOS记录号WOS:000709762800004
出版者ELSEVIER SCI LTD
源URL[http://119.78.100.183/handle/2S10ELR8/298463]  
专题新药研究国家重点实验室
通讯作者Wu, Zhibing; Huang, Yongzhuo
作者单位1.Guangzhou Univ Chinese Med, Affiliated Hosp 1, Artemisinin Res Ctr, 12 Jichang Rd, Guangzhou 510450, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
3.Chinese Acad Sci, Inst Drug Discovery & Dev, Zhongshan Inst Drug Discovery, Zhongshan 528437, Peoples R China
4.Peking Univ, Coll Chem & Mol Engn, Dept Polymer Sci & Engn, Beijing 100871, Peoples R China
5.Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou 310006, Peoples R China
6.Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China
7.Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Sch Med, Shanghai 200011, Peoples R China
8.NMPA Key Lab Qual Res & Evaluat Pharmaceut Excipi, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 Tang, Yisi,Fan, Wufa,Chen, Guihua,et al. Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment[J]. NANO TODAY,2021,40:14.
APA Tang, Yisi.,Fan, Wufa.,Chen, Guihua.,Zhang, Meng.,Tang, Xueping.,...&Huang, Yongzhuo.(2021).Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment.NANO TODAY,40,14.
MLA Tang, Yisi,et al."Recombinant cancer nanovaccine for targeting tumor-associated macrophage and remodeling tumor microenvironment".NANO TODAY 40(2021):14.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。